Skip to content
OpenCapital
Get started

Baxter International BAX Medical Products & Therapies — Depreciation

Other segment segments

Healthcare Systems & Technologies
$24M-11.1%
Pharmaceuticals
$16M0.0%

Similar metrics at other companies

Chart Industries logo
GTLSBiomedical — D&A
$1.4M-6.7%
Chart Industries logo
GTLSSpecialty Products — Depreciation expense
$7.4M+48.0%
STERIS logo
STEHealthcare Products and Life Sciences — Depreciation, Depletion and Amortization
$81.9M-4.5%
Nordson logo
NDSNMedical and Fluid Solutions — Depreciation
$7.83M-9.7%
RPM International logo
RPMSpecialty Products Group — Depreciation And Amortization
$6.38M+2.5%
Chart Industries logo
GTLSSpecialty Products — Depreciation and amortization expense
$7.4M+48.0%

Other financials

Income statement

See full
Revenue$2.7B+2.9%
Gross profit$891.0M+3.5%
Operating income$66.0M+13.8%
Net income-$15.0M-112%
EPS (diluted)-$0.03-112%

Balance sheet

See full
Cash & equivalents$2.0B-12.1%
Total debt$224.0M-8.9%
Total equity$6.0B-14.7%
Total assets$19.8B-6.8%

Cash flow

See full
Operating cash flow$213.0M+210%
CapEx$128.3M+15.0%
Free cash flow$83.0M-42.1%

Valuation

See full
Market cap$10.27B-50.6%
Enterprise value$8.48B-55.6%
P/S0.9×-1.0×

Profitability

See full
Gross margin30.1%-5.9pp
Operating margin-2.7%—
Net margin-9.7%+62.5pp
FCF margin3%-2.4pp

Returns & leverage

See full
Return on equity-16.7%-76.7pp
Debt / equity0×0.0×
Current ratio1.9×-0.2×

Where this comes from

Reported directly by Baxter International in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Baxter International’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Baxter International's medical products & therapies — depreciation.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Baxter International's medical products & therapies — depreciation?
Baxter International (BAX) reported medical products & therapies — depreciation of $51M in Q1 2026.
How has Baxter International's medical products & therapies — depreciation changed year-over-year?
Baxter International's medical products & therapies — depreciation increased by 4.1% year-over-year, from $49M to $51M.
What is the long-term trend for Baxter International's medical products & therapies — depreciation?
Over 4 years (2021 to 2025), Baxter International's medical products & therapies — depreciation has grown at a -0.8% compound annual growth rate (CAGR), from $213M to $206M.
What does medical products & therapies — depreciation mean?
The annual expense representing the wear and tear of the segment's physical assets.
How do you interpret medical products & therapies — depreciation?
High depreciation relative to assets may indicate an aging capital base, while stable levels suggest consistent investment.
How does medical products & therapies — depreciation compare across companies?
Standard non-cash expense metric for asset-intensive manufacturing segments.